Ultragenyx Pharmaceutical | RARE - Cash And Equivalent


Ultragenyx Pharmaceutical reported $125M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Immunic USD 186.63M 171.15M Mar/2026
Insmed USD 544.76M 37.42M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Kyowa Hakko Kirin JPY 218.77B 15.83B Dec/2025
MacroGenics USD 113.91M 47.39M Jun/2026
Moderna USD 1.72B 185M Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026